Cargando…
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study
BACKGROUND: We evaluated immunogenicity of SCB-2019, a subunit vaccine candidate containing a pre-fusion trimeric form of the SARS-CoV-2 spike (S)-protein adjuvanted with CpG-1018/alum. METHODS: The phase 2/3, double-blind, randomized SPECTRA trial was conducted in five countries in participants age...
Autores principales: | Buntinx, Erik, Brochado, Leonardo, Borja-Tabora, Charissa, Yu, Charles Y., Alberto, Edison R, Montellano, May Emmeline B., Carlos, Josefina C., Toloza, Leonardo Bautista, Hites, Maya, Siber, George, Clemens, Ralf, Ambrosino, Donna, Qin, Haijing, Chen, Hui Ling, Han, Htay Htay, Hu, Branda, Li, Ping, Baccarini, Carmen, Smolenov, Igor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Clover Biopharmaceuticals. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910015/ https://www.ncbi.nlm.nih.gov/pubmed/36781334 http://dx.doi.org/10.1016/j.vaccine.2023.02.017 |
Ejemplares similares
-
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
por: Lopez, Pio, et al.
Publicado: (2023) -
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial
por: Smolenov, Igor, et al.
Publicado: (2022) -
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
por: Ambrosino, Donna, et al.
Publicado: (2021) -
Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
por: Roa, Camilo C, et al.
Publicado: (2023) -
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
por: Bravo, Lulu, et al.
Publicado: (2022)